Abstract
Lung carcinoma is one of the most commonly diagnosed cancers worldwide, and the leading cause of cancer deaths across the globe. The most recent epidemiological data indicate that lung cancer is attributed to 1 in 10 (11.4%) cancers diagnosed, and 1 in 5 (18.0%) deaths worldwide. Estrogen is speculated to play an important role in lung carcinogenesis. This review data indicates a significant role of the female sex hormone β-estradiol in the etiopathogenesis, clinical treatment, and prognosis of non-squamous lung cancer (NSCLC). Estrogen activity in the growth of NSCLC tumors has been confirmed by a number of studies, and lowering the level of estrogen hormones could have a positive effect on antitumor activity in this area.
Publisher
BM-Publisher American Journal of BioMedicine
Reference40 articles.
1. 1. American Cancer Society. Key statistics for lung cancer. Available from: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
2. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis;Watanabe;Gen Thorac Cardiovasc Surg,2013
3. 3. Cancer.Net. Lung Cancer-Non-Small Cell: Statistics: ASCO; 2020 [updated 5/202012/31/20]. Available from: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics.
4. Immunotherapy in Advanced Lung Cancer;Huang;Oncology (Williston Park),2020
5. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer;Brahmer;N Engl J Med,2015